doi: 10.1158/0008-5472.CAN-15-1770
miR-892b silencing activates NF-κB and promotes aggressiveness in breast cancer
Lili Jiang1, Liang Yu2, Xin Zhang3, Fangyong Lei3, Lan Wang4, Xiangxia Liu5, Shu Wu6, Jinrong Zhu7, Geyan Wu8, Lixue Cao9, Aibin Liu10, Libing Song3,*, and Jun Li
The strength and duration of nuclear factor-kappa B (NF-κB) signaling is tightly controlled at multiple levels under physiological conditions, but the mechanism underlying constitutive activation of the NF-κB pathway in cancer remains unclear. In this study, we investigated micoRNA-mediated regulation of the NF-κB cascade in breast cancer. We report that miR-892b expression was significantly downregulated in human breast cancer specimens and correlated with poor patient survival. Overexpression of miR-892b in breast cancer cells significantly decreased tumor growth, metastatic capacity, and the ability to induce angiogenesis, whereas miR-892b depletion enhanced these properties, in vitro and in vivo. Furthermore, we demonstrate that miR-892b attenuated NF-κB signaling by directly targeting and suppressing multiple mediators of NF-κB, including TRAF2, TAK1, and TAB3, and thus, miR-892b silencing in breast cancer cells sustains NF-κB activity. Moreover, miR-892b downregulation was attributed to aberrant hypermethylation of its promoter. Taken together, our results provide insight into a new mechanism by which NF-κB signaling becomes constitutively activated in breast cancer and suggest a tumor-suppressive role for miR-829b, prompting further investigation into microRNA mimics for cancer therapy.